study protocol safety and efficacy of propranolol in newborns with retinopathy of prematurity (prop-rop) isrctn18523491研究方案的安全性和有效性,普萘洛尔在新生儿早产(prop-rop)isrctn18523491的视网膜病变.pdf

Filippi et al. BMC Pediatrics 2010, 10:83 /1471-2431/10/83 STUDY PROTOCOL Open Access Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCT 1* 2 1 1 2 2 Luca Filippi , Giacomo Cavallaro , Patrizio Fiorini , Marta Daniotti , Valentina Benedetti , Gloria Cristofori , Gabriella Araimo2 2 3 4 3 5 , Luca Ramenghi , Agostino La Torre , Pina Fortunato , Liliana Pollazzi , Giancarlo la Marca , 5 6 6 6 7 7 Sabrina Malvagia , Paola Bagnoli , Chiara Ristori , Massimo Dal Monte , Anna Rita Bilia , Benedetta Isacchi , Sandra Furlanetto7 8 8,9 10 11 2 , Francesca Tinelli , Giovanni Cioni , Gianpaolo Donzelli , Silvia Osnaghi , Fabio Mosca Abstract Background: Despite new therapeutic approaches have improved the prognosis of newborns with retinopathy of prematurity (ROP), an unfavourable structural and functional outcome still remains high. There is high pressure to develop new drugs to prevent and treat ROP. There is increasing enthusiasm for anti-VEGF drugs, but angiogenic inhibitors selective for abnormal blood vessels would be considered as an optimal treatment. In an animal experimental model of proliferative retinopathy, we have recently demonstrated that the pharmacological blockade of beta-adrenoreceptors improves retinal neovascularization and bloo